IL5 and non-small cell lung carcinoma: It turned out that NSCLC patients whose serum IL-5 and IFN-γ initially decreased had longer progression-free survival than those who initially increased (median PFS (months): early decreases cohort: 11.2 (IL-5), 10.8 (IFN-γ) versus early increases cohort: 6.75 (IL-5), 7.3 (IFN-γ)) (Figures 4(a) and 4(b)).